目的  探讨法舒地尔对早期糖尿病肾病患者血清转化生长因子-β1和单核细胞趋化因子1水平的影响。方法  将早期2型糖尿病肾病患者100例随机分为A组（对照组，50例）和B组（50例）。两组均给予常规治疗，B组在常规药物治疗同时给予法舒地尔注射液30mg+生理盐水50mL，2次/d，静脉泵入，连用2周。用ELISA法检测两组患者治疗前后血清转化生长因子-β1和单核细胞趋化因子1水平的变化。结果  A组治疗前后血清转化生长因子-β1和单核细胞趋化因子1水平比较，差异无统计学意义（P>0.05），B组治疗后血清转化生长因子-β1和单核细胞趋化因子1水平较治疗前下降（P<0.05），A组与B组治疗后比较，两项指标的差异均有统计学意义（P<0.05）。结论  在常规治疗的基础上加用法舒地尔注射液，可降低转化生长因子-β1和单核细胞趋化因子1水平，对早期糖尿病肾病具有良好的治疗效果。

Abstract: Objective To explore the changes of serum TGF-β1 and MCP-1 in diabetic nephrosis patients after treated with Fasudil injection. Methods 100 early diabetic nephrosis patients were randomly divided into the group A (control group, 50 cases) and group B (50 cases). All patients received routine therapy, while patients in group B were additionally given fasudil injection for 2 weeks. The level of serum TGF-β1 and MCP-1 were measured by the ELISA before and after the treatment. Results After the treatment, the levels of TGF-β1 and MCP-1 in group A had not significant changes (P>0.05), While the levels of TGF-β1 and MCP-1 in group B after treatment were much lower than that of before treatment (P<0.05). The decrease of TGF-β1 and MCP-1 were more significant in group B than that of in group A after treatment (P<0.05). Conclusion On the basis of routine therapy, Fasudil injection could inhibit the expression of TGF-β1 and MCP-1, which has good curative effect on early diabetic nephrosis.